| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ATRA | CTRPv2 | pan-cancer | AAC | 0.15 | 7e-05 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | 0.13 | 8e-05 |
| mRNA | Vorinostat | GDSC1000 | pan-cancer | AAC | 0.13 | 9e-05 |
| mRNA | TG-101348 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0001 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.19 | 0.0002 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0002 |
| mRNA | RO-3306 | GDSC1000 | pan-cancer | AAC | -0.14 | 0.0002 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0002 |
| mRNA | FK866 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0002 |
| mRNA | CHIR-99021 | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0003 |